Skip to main
ALEC
ALEC logo

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 20%
Sell 20%
Strong Sell 0%

Bulls say

Alector Inc. is developing an innovative therapeutic approach targeting neurodegeneration through its pipeline products, including the promising AL001, AL002, AL003, and AL101, which could lead to significant advancements in brain and systemic health. The company's ABC platform demonstrates superior CNS delivery capabilities compared to traditional systems, evidenced by impressive brain uptake rates of 18-32x in non-human primates, suggesting a robust competitive position in the biopharmaceutical landscape. Furthermore, the anticipated early clinical proof-of-concept data from Alector's lead programs, particularly those targeting larger indications with standardized AD biomarkers, offers a potentially substantial upside for investors and strengthens the overall outlook for the company's stock.

Bears say

Alector Inc. has faced significant setbacks as the INFRONT-3 trial for latozinemab failed to achieve its primary endpoint, raising concerns about the efficacy of its therapeutic approach to neurodegeneration. The company confronts heightened translational biology risks following unfavorable results in previous trials, suggesting inefficiencies in the transport of PGRN, which undermines its treatment potential. Alector's investment thesis is further jeopardized by the possibility of failures in ongoing clinical studies for its other pipeline products, AL001, AL002, and AL101, which may prevent regulatory approvals and hinder expected revenue growth.

Alector Inc (ALEC) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 5 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.